Zydus' Indomethacin suppositories also been granted 180-day CGT exclusivity to market this product.
Zydus becomes the only Indian oncology player to venture into prognosis and diagnosis along with treatment planning
NULIBRY is a first-in-class cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A.
The drug will be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ, India
MonoFerric, iron isomaltoside 1000 solution for injection/infusion, is a rapid, single dose IV iron developed to reduce the number of infusions
The addition of Sitaglyn and Siglyn to our diabetes portfolio will give patients access to a world-class oral therapy to help people manage their diabetes
It is a new class of drug that treats uncontrolled LDLCholesterol, despite the use of a maximum tolerated dose of statins
The two-dose regimen for ZyCoV-D was tested in 3100 healthy volunteers more than 12 years of age
Nulibry is approved by the U.S. Food and Drug Administration (USFDA) to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A, an ultra-rare, life-threatening paediatric genetic disorder
Zydus unveils its ‘innovation and care’ centric corporate brand identity
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)